As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approa...
Category: Conferences
-
November 6, 2024
Join Us at SITC 2024 to Discover SUPLEXA’s Breakthrough Potential in Cancer Immunotherapy.
-
October 30, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the scrip...
-
October 13, 2024
Alloplex’s Groundbreaking Cancer Immunotherapy Selected for SITC24 ‘Top 100’ Presentation
Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November. Two abstracts featuring SUPLEXA have been accepted for pos...
-
September 30, 2024
Dr. Borriello to present at live webinar on Immuno-Oncology R&D Challenges
Dr. Borriello will be a featured speaker at an upcoming live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, being moderated by Lumanity,...
-
June 12, 2024
SITC23 Posters with Oral Presentation recording by Alloplex Biotherapeutics Inc’s Founder and Chief Executive Officer, Dr. Frank Borriello.
SITC 2023 Poster 381 and 727 with Audio Commentary by Dr. Borriello
-
September 7, 2023
Two abstracts on Alloplex’s lead technology platform, SUPLEXA, accepted for presentation at SITC23
Dr. Rohit Joshi of CRSA and Alloplex's leadership team will present the latest developments and data from SUPLEXA-101 phase 1 in-human trials in San Diego, CA (November 1 - 5, 2023)
The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex lea...
-
August 22, 2023
Alloplex seeks strategic partners and investor meetings at LSX Leaders Congress (Boston, September 2023)
SUPLEXA cellular therapy, a highly differentiated therapy with exceptionally broad promise, has demonstrated single-agent activity in end-stage solid cancer patients
Alloplex’s founder and CEO, Dr. Frank Borriello, will be attending the upcoming LSX Leaders Congress in Boston on September 13 and 14 at the Hynes Convention Centre. Alloplex is seeking strategic partners and investors to support a de-risked Phase 2 ready clinical stage cellular therapy opport...
-
July 25, 2023
Dr. Borriello to present at CHI immuno-oncology summit 2023 in Boston
Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9. The session starts at 8.55 am and Dr. Borriello’s p...
-
June 14, 2023
Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe
Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023. His presentation,...
-
May 22, 2023
Dr. Borriello attending Immuno-Oncology Xchange East Coast 2023
Alloplex CEO to participate in round table discussions
Alloplex is pleased to announce its participation in the US East Coast Immuno-Oncology Xchange to be held in Boston on May 23, 2023. Our CEO, Frank Borriello, will be in attendance and participate in a number of round table discussions. Specifically, SUPLEXA therapeutic cells will be discussed in th...
-
April 19, 2023
Alloplex to present emerging data from SUPLEXA-101 trial at World Oncology Cell Therapy Congress 2023 in Boston
The presentation will also highlight the development of an unprecedented blood-based pharmacodynamic signature of SUPLEXA activity
We are pleased to announce that Dr. Frank Borriello, Founder and CEO of Alloplex Biotherapeutics, will be presenting at the upcoming World Oncology Cell Therapy Congress, being held in Boston, MA, on April 25 & 26, 2023. The presentation will include emerging data from t...
-
July 27, 2022
Dr. Frank Borriello to speak at Gamma Delta T Therapies Summit.
July 28, 2022 in Boston.
Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11am in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous...
-
February 20, 2022
Alloplex to present Poster at AACR 2022
Alloplex’s Abstract (3599) ‘Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells’ has been accepted by AACR and is scheduled for presentation in a Poster session at the 2022 Annual Meeting. We look forward to attending this yea...
-
November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufact...
-
March 22, 2021
Alloplex Biotherapeutics will attend the Innate Killer Cell Conference
The Innate Killer Cell Conference on March 24-25, 2021 held by Hanson Wade.
-
August 3, 2020
Alloplex Biotherapeutics to Present at the LifeSci Partners Summer Symposium
Alloplex CEO Frank Borriello MD, PhD will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020.
-
May 4, 2020
Alloplex Biotherapeutics Announces Participation in the Cancer Progress Meeting
Alloplex Biotherapeutics announces its participation in the Cancer Progress Meeting to be held virtually on May 5-6, 2020.